Pfizer's Dividend Puzzle: A High Stakes Game of Patent Expiration Pfizer has relied heavily on its massive dividend payments to attract investors, but a closer look at the company's financials reveals a more nuanced story.
The 7% dividend yield may seem attractive compared to the broader market, but it comes with significant risks.
The pharmaceutical giant's aggressive dividend payout strategy has been fueled by cash flows that have reached $14. 6 billion over the last 18 months.